X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

RA medicines often demonstrate far greater benefits to patients than initially understood

By Lauren Neves  |    April 5, 2017
In the last decade, new therapies to treat rheumatoid arthritis (RA), a progressive and painful autoimmune disorder, have expanded patients’ treatment options and significantly improved outcomes,...   Read More

Stakeholders Agree: Modernize the legal framework to support move to value-driven health care

By Michelle Drozd  |    March 6, 2017
Modernizing certain laws and regulations to support the move to value-driven health care is an important step in moving our health care system forward. As part of PhRMA’s proactive policy...   Read More

How do multiple sclerosis patients define value?

By Lauren Neves  |    February 24, 2017
There are crucial conversations occurring in the health care system about how value is defined. To explore how multiple sclerosis (MS) patients, providers and payers view value, Real Endpoints...   Read More

PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check

By Holly Campbell  |    February 9, 2017
Following the biopharmaceutical industry’s recent meeting with President  Donald J. Trump, PhRMA president and CEO Stephen J. Ubl joined Dan Diamond on POLITICO’s Pulse Check podcast to discuss...   Read More

VIDEO: PhRMA CEO joins Fox Business anchor Neil Cavuto to discuss personal connection to value of innovation and White House meeting

By Holly Campbell  |    February 6, 2017
PhRMA president and CEO Stephen J. Ubl recently spoke with FOX Business anchor Neil Cavuto on his personal connection to the value of medical technology with his son’s type 1 diabetes diagnosis,...   Read More

VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake

By Holly Campbell  |    February 3, 2017
PhRMA president and CEO Stephen J. Ubl joined Maggie Lake on CNNMoney this week to talk about the industry’s new national campaign, GOBOLDLY™, and meeting with President Donald J. Trump. He also...   Read More

The Value Collaborative: Advancing private market solutions to achieve better health, lower costs

By Stephen J. Ubl  |    January 31, 2017
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY™, our new...   Read More

ICER glosses over significant progress in MS treatment

By Holly Campbell  |    November 30, 2016
Multiple sclerosis (MS) is a devastating chronic autoimmune disease that can affect a person’s brain, spinal cord and optic nerves, causing problems with vision, balance, muscle control and other...   Read More

Stakeholders raise concerns about ICER’s evidence report for non-small cell lung cancer

By Lauren Neves  |    October 20, 2016
The value of recent advances in non-small cell lung cancer (NSCLC) is undeniable. NSCLC is a devastating illness – 17.7 percent of lung cancer patients survive only five years following their...   Read More

Panel releases best practices in cost-effectiveness analysis

By Lauren Neves  |    October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates